Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Kitsada Wudhikarn, Jessica R. Flynn, Isabelle Rivière, Mithat Gönen, Xiuyan Wang, Brigitte Senechal, Kevin J. Curran, Mikhail Roshal, Peter G. Maslak, Mark B. Geyer, Elizabeth F. Halton, Claudia Diamonte, Marco L. Davila, Michel Sadelain, Renier J. Brentjens, Jae H. Park

Blood (2021) 138 (7): 531–543.

https://doi.org/10.1182/blood.2020009515

Published: 2021

Includes: Supplemental data

Journal Articles

Chronic Myeloid Leukemia After Adjuvant Treatment For Breast Cancer: Is It Therapy Related?

Ashwin Kishtagari, MBBS, Isaac Alexander Bowman, MD, Martin S. Tallman, MD, Dan Douer, MD, Ellin Berman, MD, Peter G. Maslak, M.D., Renier J Brentjens, MD, PhD, Eytan M Stein, MD

Blood (2013) 122 (21): 2740.

https://doi.org/10.1182/blood.V122.21.2740.2740

Published: 2013

Journal Articles

Multiparameter Flow Cytometry For Detection Of Minimal Residual Disease In Multiple Myeloma After T-Cell Depleted Allogeneic Stem Cell Transplant

Satyajit Kosuri, MD, Katherine M Smith, BA, Deborah Kuk, MS, Sean M. Devlin, PhD, Peter G. Maslak, M.D., Sergio Giralt, MD, Guenther Koehne, MD, PhD

Blood (2013) 122 (21): 4647.

https://doi.org/10.1182/blood.V122.21.4647.4647

Published: 2013

Journal Articles

Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.

Jeffrey R Gardner, MBA, Sean Devlin, PhD, Kristina Knapp, Francesco Bauli, MS, Nicole Lamanna, MD, Mark G. Frattini, MD, PhD, Renier J Brentjens, MD, PhD, Peter G. Maslak, M.D., Joseph G. Jurcic, MD, Mark Weiss, MD, David A. Scheinberg, MD, PhD, Mark Heaney, MD, PhD

Blood (2012) 120 (21): 2482.

https://doi.org/10.1182/blood.V120.21.2482.2482

Published: 2012

Journal Articles

Potential Clinical Impact of Inaccurate Automated Platelet Counts in the Setting of Severe Thrombocytopenia

Steven M. Marionneaux, MS, MT(ASCP), Peter G. Maslak, M.D., Nenita Francisco, MT, Virgil Chan, MT(ASCP), Justin Hanenberg, MT(ASCP), Jean Lynch, MT(ASCP), Josephine Rafael, MT(ASCP), Jingqiu Yao, MT, Conchita Chua, MT(ASCP)

Blood (2012) 120 (21): 3428.

https://doi.org/10.1182/blood.V120.21.3428.3428

Published: 2012

Journal Articles

High Dose Cytarabine and Mitoxantrone in Combination with Dasatinib As Active Induction Therapy in Adult Patients with Philadelphia Chromosome Positive (ph+) Acute Lymphoblastic Leukemia (ALL)

Nicole Lamanna, MD, Mark Weiss, MD, Ellin Berman, MD, Mark G. Frattini, MD, PhD, Mark Heaney, MD, PhD, Joseph G. Jurcic, MD, Todd L. Rosenblat, MD, Heather Landau, MD, Hanna Weissbrot, BA, Peter G. Maslak, M.D.

Blood (2012) 120 (21): 4293.

https://doi.org/10.1182/blood.V120.21.4293.4293

Published: 2012

Journal Articles

Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR)

Todd L. Rosenblat, MD, Mark G. Frattini, MD, PhD, Suzanne M. Chanel, RN, Tao Dao, MD, PhD, Yvette Bernal, Joseph G. Jurcic, MD, Rhong Zhang, Pamela Simancek, Martin S Tallman, MD, David A. Scheinberg, MD, PhD, Peter G. Maslak, M.D.

Blood (2012) 120 (21): 3624.

https://doi.org/10.1182/blood.V120.21.3624.3624

Published: 2012

Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne M. Chanel, RN, Kevin Zikaras, BS, Mark G. Frattini, MD, PhD, Peter G. Maslak, M.D., Dragan Cicic, MD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD

Blood (2011) 118 (21): 768.

https://doi.org/10.1182/blood.V118.21.768.768

Published: 2011

Journal Articles

Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center

Ellin Berman, MD, Cyrus V. Hedvat, MD, PhD, Joseph G. Jurcic, MD, Mark Heaney, MD, PhD, Peter G. Maslak, M.D., Renier Brentjens, MD, PhD, Nicole Lamanna, MD, Todd L. Rosenblat, MD, Mark G. Frattini, MD, PhD, Ann A Jakubowski, MD, PhD, Suresh Jhanwar, PhD

Blood (2011) 118 (21): 4433.

https://doi.org/10.1182/blood.V118.21.4433.4433

Published: 2011

Journal Articles

Translocation t(11;17) Is Not Always Associated with Acute Myeloid or Acute Promyelocytic Leukemia

Muhamed Baljevic, M.D., Suresh C. Jhanwar, PhD, Todd L. Rosenblat, MD, Peter G. Maslak, M.D., Dan Douer, M.D., Martin S. Tallman, MD

Blood (2011) 118 (21): 5044.

https://doi.org/10.1182/blood.V118.21.5044.5044

Published: 2011

Journal Articles

Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History

Jeffrey R Gardner, MBA, Kristina Knapp, Mark G. Frattini, MD, PhD, Nicole Lamanna, MD, Renier Brentjens, MD, PhD, Joseph G Jurcic, MD, Peter G. Maslak, M.D., Ellin Berman, MD, Mark Weiss, MD, David A. Scheinberg, MD, PhD, Mark Heaney, MD, PhD

Blood (2011) 118 (21): 1765.

https://doi.org/10.1182/blood.V118.21.1765.1765

Published: 2011

Journal Articles

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia

Peter G. Maslak, Tao Dao, Lee M. Krug, Suzanne Chanel, Tatyana Korontsvit, Victoria Zakhaleva, Ronghua Zhang, Jedd D. Wolchok, Jianda Yuan, Javier Pinilla-Ibarz, Ellin Berman, Mark Weiss, Joseph Jurcic, Mark G. Frattini, David A. Scheinberg

Blood (2010) 116 (2): 171–179.

https://doi.org/10.1182/blood-2009-10-250993

Published: 2010

Journal Articles

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody–based therapy

Ping Zhou, Raymond L. Comenzo, Adam B. Olshen, Ezio Bonvini, Scott Koenig, Peter G. Maslak, Martin Fleisher, James Hoffman, Suresh Jhanwar, James W. Young, Stephen D. Nimer, Adam M. Boruchov

Blood (2008) 111 (7): 3403–3406.

https://doi.org/10.1182/blood-2007-11-125526

Published: 2008

Journal Articles

Pilot Study of a Wilms Tumor Protein (WT1) Heteroclitic Peptide Vaccine in Patients with Myeloid and Thoracic Neoplasms.

Peter G. Maslak, MD, Lee Krug, MD, Suzanne Chanel, RN, Tao Dao, PhD, Leonard James, MD, PhD, Leslie Tyson, RN, Sara Bekele, BA, David A. Scheinberg, MD, PhD

Blood (2007) 110 (11): 903.

https://doi.org/10.1182/blood.V110.11.903.903

Published: 2007

Journal Articles

Induction with Combined Modality Therapy Followed by Immunomodulated Post Remission Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML).

Seema Gupta, MD, Mark A. Weiss, MD, Joseph G. Jurcic, MD, Suzanne Chanel, RN, Bri-Anne Wilson, BA, Emily Biederman, BA, Ellin Berman, MD, David A. Scheinberg, MD, PhD, Peter G. Maslak, MD

Blood (2005) 106 (11): 2802.

https://doi.org/10.1182/blood.V106.11.2802.2802

Published: 2005

NARROW

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Chronic Myeloid Leukemia After Adjuvant Treatment For Breast Cancer: Is It Therapy Related?

Multiparameter Flow Cytometry For Detection Of Minimal Residual Disease In Multiple Myeloma After T-Cell Depleted Allogeneic Stem Cell Transplant

Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.

Potential Clinical Impact of Inaccurate Automated Platelet Counts in the Setting of Severe Thrombocytopenia

High Dose Cytarabine and Mitoxantrone in Combination with Dasatinib As Active Induction Therapy in Adult Patients with Philadelphia Chromosome Positive (ph+) Acute Lymphoblastic Leukemia (ALL)

Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR)

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center

Translocation t(11;17) Is Not Always Associated with Acute Myeloid or Acute Promyelocytic Leukemia

Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody–based therapy

Pilot Study of a Wilms Tumor Protein (WT1) Heteroclitic Peptide Vaccine in Patients with Myeloid and Thoracic Neoplasms.

Induction with Combined Modality Therapy Followed by Immunomodulated Post Remission Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only